The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Integrative Clinical Genomics of Advanced Prostate Cancer
Open accessAbstract
Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF. Moreover, aberrations of BRCA2, BRCA1, and ATM were observed at substantially higher frequencies (19.3% overall) compared to those in primary prostate cancers. 89% of affected individuals harbored a clinically actionable aberration, including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. This cohort study provides clinically actionable information that could impact treatment decisions for these affected individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The androgen receptor (AR) is a critical driver of prostate cancer (PCa).”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“The consortium utilized two sequencing and analysis centers, one centralized digital pathology review center, and one centralized data visualization portal (Cerami et al., 2012; Gao et al., 2013; Robinson et al., 2011; Thorvaldsdóttir et al., 2013).”
Self-citationRobinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 3×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationTrapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · cited 1×
“…analysis reveals that the majority of affected individuals with metastatic castration-resistant prostate cancer harbor clinically actionable molecular alterations, highlighting the need for genetic counseling to inform precision medicine in affected individuals with advanced prostate cancer.”
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965 · cited 2×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Self-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · cited 1×
“…on the PI3K pathway, PIK3CB-specific inhibitors may have utility in affected individuals with mutation, amplification, and/or fusion of this gene (Schwartz et al., 2015); multiple affected individuals who achieved durable (>1 year) responses to PIK3CB-specificin inhibition harbored activating…”
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Self-citationRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · cited 1×
“Among chimeric fusion transcripts identified, recurrent ETS fusions (Tomlins et al., 2005) were observed in 84 cases (56%), of which the majority were fused to ERG and others to FLI1, ETV4, and ETV5 (Figure 3B).”
Self-citation
Cited by
Sorted by citations
Items 801–900 of 1,007
Biomarkers in Localized Prostate Cancer
Ferro, M., Buonerba, C., Terracciano, D., Lucarelli, G. T., Cosimato, V., Bottero, D., Deliu, V. M., Ditonno, P., Perdonà, S., Riccardo Autorino, B., et al. (2016) · Future Oncology · doi:10.2217/fon.15.318 · Cited by 51
Zanetti, D., Rao, A. S., Gustafsson, S., Assimes, T. L., Montgomery, S. B., & Ingelsson, E. (2019) · Kidney International · doi:10.1016/j.kint.2018.12.017 · Cited by 51
DNA Damage Repair Deficiency in Prostate Cancer
Burdak‐Rothkamm, S., Mansour, W. Y., & Rothkamm, K. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.05.011 · Cited by 53
Connor, M. J., Smith, A., Miah, S., Shah, T. T., Winkler, M. H., Khoo, V. S., & Ahmed, H. U. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.07.004 · Cited by 51
N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer
Wu, Q., Xie, X., Huang, Y., Meng, S., Li, Y., Wang, H.-F., & Hu, Y. (2020) · Journal of Cancer · doi:10.7150/jca.46379 · Cited by 51
Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic EraPreprint
Arriaga, J. M., & Abate-Shen, C. T. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030528 · Cited by 56
Allosteric interactions prime androgen receptor dimerization and activation
Wasmuth, E. V., Broeck, A. V., LaClair, J. R., Hoover, E. A., Lawrence, K. E., Paknejad, N., Pappas, K., Matthies, D., Wang, B., Feng, W., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.03.035 · Cited by 50
Self-citationClinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker
Ionescu, F., Zhang, J., & Wang, L. (2022) · Cancers · doi:10.3390/cancers14071728 · Cited by 49
Zhang, D., Xu, X., Wei, Y., Chen, X., Li, G., Lü, Z., Zhang, X., Ren, X., Wang, S., & Qin, C. (2022) · Cancer Control · doi:10.1177/10732748221129451 · Cited by 50
Matsubara, N., Bono, J. S. D., Olmos, D., Procopio, G., Kawakami, S., Ürün, Y., van Alphen, R., Fléchon, A., Carducci, M. A., Choi, Y. D., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3577 · Cited by 51
Self-citationBRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype
Fettke, H., Dai, C., Kwan, E. M., Zheng, T., Du, P., Ng, N., Bukczynska, P. E., Docanto, M. M., Kostos, L. K., Foroughi, S., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104738 · Cited by 48
Burris, T. P., de Vera, I. M. S., Côté, I., Flaveny, C. A., Wanninayake, U. S., Chatterjee, A., Walker, J. K., Steinauer, N., Zhang, J., Coons, L. A., et al. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000436 · Cited by 54
Development of PARP inhibitors in advanced prostate cancer
Bourlon, M. T., Valdez-Sandoval, P. I., & Castro, E. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231221337 · Cited by 53
“3,4 Among these genes, the HRR pathway is the most commonly impaired DNA repair pathway in prostate cancer.”
BackgroundDiscovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors
Fried, W., Tyagi, M., Станиславович, М. Л., Chandramouly, G., Tredinnick, T., Ramanjulu, M. M., Auerbacher, W., Calbert, M. L., Rusanov, T., Hoàng, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46593-1 · Cited by 53
“Integrative clinical genomics of advanced prostate cancer revealed that >10% of metastatic castration-resistant prostate cancers (mCRPCs) exhibit biallelic loss of BRCA2 42 , and Olaparib has been approved to treat BRCA-mutant mCRPC 6 .”
BackgroundKu, S., Wang, Y., Garcia, M. M., Yamada, Y., Mizuno, K., Long, M. D., Rosario, S. R., Chinnam, M., Assaad, M. A., Puca, L., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175217 · Cited by 50
“While mutations involving Notch pathway genes are not typically seen in prostate cancer, including NEPC (66, 67), epigenetic modifications associated with the suppression of Notch signaling genes may be observed.”
BackgroundSelf-citationHussain, M., Kocherginsky, M., Agarwal, N., Adra, N., Zhang, J., Paller, C. J., Picus, J., Reichert, Z. R., Szmulewitz, R. Z., Tagawa, S. T., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1402 · Cited by 52
Self-citationThe role of peroxisome proliferator-activated receptor gamma in prostate cancer
Jones, J., Elix, C. C., & Pal, S. (2017) · Asian Journal of Andrology · doi:10.4103/aja.aja_15_17 · Cited by 51
PI3Kβ—A Versatile Transducer for GPCR, RTK, and Small GTPase Signaling
Bresnick, A. R., & Backer, J. (2019) · Endocrinology · doi:10.1210/en.2018-00843 · Cited by 52
Targeting the androgen receptor and overcoming resistance in prostate cancer
Einstein, D. J., Arai, S., & Balk, S. P. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000520 · Cited by 50
Self-citationClonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma
Laudato, S., Aparicio, A. M., & Giancotti, F. G. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.05.008 · Cited by 50
Helleday, T. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw048 · Cited by 50
Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor HeterogeneityPreprint
Miyamoto, D. T., Ting, D. T., Toner, M., Maheswaran, S., & Haber, D. A. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031120 · Cited by 51
Wasmuth, E. V., Hoover, E. A., Antar, A., Klinge, S., Chen, Y., & Sawyers, C. L. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922159117 · Cited by 50
Self-citationWatanabe, R., Miura, N., Kurata, M., Kitazawa, R., Kikugawa, T., & Saika, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108955 · Cited by 49
“Meanwhile, a high rate of HRR gene mutations has been reported in t-NEPC, which is similar to the mutation profile in advanced prostate cancer [23].”
ResultOptimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer
Lorente, D., Fizazi, K. S., Sweeney, C. J., & Bono, J. S. D. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.10.008 · Cited by 51
Kalyvianaki, K., Gebhart, V. M., Peroulis, N., Panagiotopoulou, C., Kiagiadaki, F., Pediaditakis, I., Aivaliotis, M., Moustou, E., Tzardi, M. N., Notas, G., et al. (2017) · Scientific Reports · doi:10.1038/srep44418 · Cited by 49
PRDM4 mediates YAP‐induced cell invasion by activating leukocyte‐specific integrin β2 expression
Liu, H., Dai, X., Cao, X., Yan, H., Ji, X., Zhang, H., Shen, S., Si, Y., Zhang, H., Chen, J., et al. (2018) · EMBO Reports · doi:10.15252/embr.201745180 · Cited by 50
Self-citationEbron, J. S., Shankar, E., Singh, J., Sikand, K., Weyman, C. M., Gupta, S., Lindner, D. J., Liu, X., Campbell, M. J., & Shukla, G. C. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2993 · Cited by 49
Carm, K. T., Hoff, A., Bakken, A. C., Axcrona, U., Axcrona, K., Lothe, R. A., Skotheim, R. I., & Løvf, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-49964-7 · Cited by 49
Saraç, H., Morova, T., Pires, E., McCullagh, J., Kaplan, A., Cingöz, A., Onder, T. B., Önder, T. T., Kawamura, A., & Lack, N. A. (2019) · Oncogene · doi:10.1038/s41388-019-1116-8 · Cited by 50
Fizazi, K., Clarke, N. W., De Santis, M., Uemura, H., Fay, A. P., Karadurmus, N., Kwiatkowski, M., Alvarez-Fernandez, C., Jiang, S., Sotelo, M., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.004 · Cited by 55
Self-citationScott, R. J., Mehta, A., Macedo, G. S., Borisov, P. S., Kanesvaran, R., & El-Metnawy, W. (2021) · Oncotarget · doi:10.18632/oncotarget.28015 · Cited by 49
Androgen Receptor-Mediated Transcription in Prostate Cancer
Özturan, D., Morova, T., & Lack, N. A. (2022) · Cells · doi:10.3390/cells11050898 · Cited by 51
Kim, J. W., McKay, R. R., Radke, M. R., Zhao, S., Taplin, M., Davis, N. B., Monk, P., Appleman, L. J., Lara, P. N., Vaishampayan, U. N., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02947 · Cited by 50
Self-citationWarner, E. W., der Eecken, K. V., Murtha, A. J., Kwan, E. M., Herberts, C., Sipola, J., Ng, S. W. S., Chen, X. E., Fonseca, N. M., Ritch, E. J., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00692-y · Cited by 47
Sunkel, B. D., Wu, D., Chen, Z., Wang, C., Liu, X., Ye, Z., Horning, A. M., Liu, J., Mahalingam, D., Lopez-Nicora, H. D., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1528 · Cited by 48
Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms
Gulati, R., Cheng, H. H., Lange, P. H., Nelson, P. S., & Etzioni, R. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0434 · Cited by 48
Self-citationKedage, V., Selvaraj, N., Nicholas, T. R., Budka, J. A., Plotnik, J. P., Jerde, T. J., & Hollenhorst, P. C. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.001 · Cited by 52
Role of steroid receptor and coregulator mutations in hormone-dependent cancers
Groner, A. C., & Brown, M. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88885 · Cited by 49
Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification
Inamura, K. (2018) · Oncotarget · doi:10.18632/oncotarget.24515 · Cited by 51
Belic, J., Graf, R., Bauernhofer, T., Cherkas, Y., Ulz, P., Waldispuehl‐Geigl, J., Perakis, S. O., Gormley, M., Patel, J., Li, W., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31397 · Cited by 49
Emerging therapeutic agents for genitourinary cancers
Zarrabi, K. K., Paroya, A., & Wu, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0780-z · Cited by 49
Ledet, E. M., Lilly, M. B., Sonpavde, G., Lin, E., Nussenzveig, R. H., Barata, P. C., Yandell, M. D., Nagy, R. J., Kiedrowski, L. A., Agarwal, N., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0115 · Cited by 48
FHIR Genomics: enabling standardization for precision medicine use cases
Alterovitz, G., Heale, B. S. E., Jones, J., Kreda, D., Lin, F., Liu, L., Liu, X., Mandl, K. D., Poloway, D., Ramoni, R. B., et al. (2020) · npj Genomic Medicine · doi:10.1038/s41525-020-0115-6 · Cited by 48
Sugiura, M., Sato, H., Okabe, A., Fukuyo, M., Mano, Y., Shinohara, K.-I., Rahmutulla, B., Higuchi, K., Maimaiti, M., Kanesaka, M., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100915 · Cited by 49
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
Conteduca, V., Mosca, A., Brighi, N., Giorgi, U. D., & Rescigno, P. (2021) · Cells · doi:10.3390/cells10010193 · Cited by 52
Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer
Liu, Z., Wang, P., Wold, E. A., Song, Q., Zhao, C., Wang, C., & Zhou, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01799 · Cited by 50
Novel insights in cell cycle dysregulation during prostate cancer progression
Ben‐Salem, S., & Venkadakrishnan, V. B. (2021) · Endocrine Related Cancer · doi:10.1530/erc-20-0517 · Cited by 52
H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility
Giambartolomei, C., Seo, J.-H., Schwarz, T., Freund, M. K., Johnson, R., Spisák, S., Baca, S. C., Gusev, A., Mancuso, N., Paşaniuc, B., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.11.007 · Cited by 49
Regulation of AR mRNA translation in response to acute AR pathway inhibition
Somasekharan, S. P., Saxena, N., Zhang, F., Beraldi, E., Huang, J. N., Gentle, C., Fazli, L., Thi, M., Sorensen, P. H. B., & Gleave, M. E. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1247 · Cited by 48
Exploring the Wnt Pathway as a Therapeutic Target for Prostate Cancer
Koushyar, S., Méniel, V. S., Phesse, T. J., & Pearson, H. B. (2022) · Biomolecules · doi:10.3390/biom12020309 · Cited by 48
Nevedomskaya, E., & Haendler, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116281 · Cited by 49
Shangguan, X., Ma, Z., Yu, M., Ding, J., Xue, W., & Qi, J. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3822 · Cited by 48
Kanesvaran, R., Castro, E., Wong, A. S. C., Fizazi, K. S., Chua, M. L. K., Zhu, Y., Malhotra, H., Miura, Y., Lee, J. L., Chong, F. L. T., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100518 · Cited by 47
STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer
Mohanty, S. K., Yagiz, K., Pradhan, D., Luthringer, D., Amin, M. B., Alkan, S., & Cinar, B. (2017) · Oncotarget · doi:10.18632/oncotarget.20844 · Cited by 47
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives
Mosillo, C., Iacovelli, R., Ciccarese, C., Fantinel, E., Bimbatti, D., Brunelli, M., Bisogno, I., Kinspergher, S., Buttigliero, C., Tucci, M., et al. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.005 · Cited by 47
González‐Billalabeitia, E., Conteduca, V., Wetterskog, D., Jayaram, A., & Attard, G. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0098-x · Cited by 49
Self-citationProstate-specific markers to identify rare prostate cancer cells in liquid biopsies
van der Toom, E. E., Axelrod, H. D., de la Rosette, J. J. M. C. H., de Reijke, T. M., Pienta, K. J., & Valkenburg, K. C. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0119-5 · Cited by 48
Self-citationThe PHLPP2 phosphatase is a druggable driver of prostate cancer progression
Nowak, D. G., Cohen‐Katsenelson, K., Watrud, K. E., Chen, M., Mathew, G., D’Andrea, V. D., Lee, M. F., Swamynathan, M. M., Casanova‐Salas, I., Jibilian, M. C., et al. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201902048 · Cited by 49
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations
Lu, C., Brown, L. C., Antonarakis, E. S., Armstrong, A. J., & Luo, J. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0217-3 · Cited by 48
Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion
Wang, Y., Singhal, U., Qiao, Y., Kasputis, T., Chung, J., Zhao, H., Chammaa, F., Belardo, J. A., Roth, T. M., Zhang, H., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100747 · Cited by 47
Self-citationVanOpstall, C., Perike, S., Brechka, H., Gillard, M., Lamperis, S. M., Zhu, B., Brown, R. M., Bhanvadia, R. R., & Griend, D. J. V. (2020) · eLife · doi:10.7554/elife.53600 · Cited by 47
Targetable gene fusions and aberrations in genitourinary oncology
Pederzoli, F., Bandini, M., Marandino, L., Ali, S. M., Madison, R. W., Chung, J., Ross, J. S., & Necchi, A. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-00379-4 · Cited by 49
Cattrini, C., Caffo, O., Giorgi, U. D., Mennitto, A., Gennari, A., Olmos, D., & Castro, E. (2022) · Cancers · doi:10.3390/cancers14071792 · Cited by 47
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Bernasocchi, T., Tekle, G. E., Bolis, M., Mutti, A., Vallerga, A., Brandt, L. P., Spriano, F., Svinkina, T., Zoma, M., Ceserani, V., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20820-x · Cited by 46
Self-citationGlycosylation Changes in Prostate Cancer Progression
Butler, W., & Huang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.809170 · Cited by 48
Advances with androgen deprivation therapy for prostate cancer
Yu, E.-M., & Aragon‐Ching, J. B. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2033210 · Cited by 49
Self-citationFuture directions for precision oncology in prostate cancer
Mizuno, K., & Beltran, H. (2022) · The Prostate · doi:10.1002/pros.24354 · Cited by 49
Self-citationPARP Inhibitors: A New Horizon for Patients with Prostate Cancer
Congregado, B., BELENCHON, I. R., Osman, I., Sáez, C., & López, R. A. M. (2022) · Biomedicines · doi:10.3390/biomedicines10061416 · Cited by 48
Gorodetska, I., Offermann, A., Püschel, J., Lukiyanchuk, V., Gaete, D., Kurzyukova, A., Freytag, V., Haider, M., Fjeldbo, C. S., Gaetano, S. D., et al. (2024) · Theranostics · doi:10.7150/thno.88057 · Cited by 47
Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors
Decker, B. J., Karyadi, D. M., Davis, B. W., Karlins, E., Tillmans, L. S., Stanford, J. L., Thibodeau, S. N., & Ostrander, E. A. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.03.003 · Cited by 48
Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer
Roubaud, G., Liaw, B. C.-H., Oh, W. K., & Mulholland, D. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.181 · Cited by 46
Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)
Spreafico, A., Oza, A. M., Clarke, B. A., MacKay, H. J., Shaw, P. H., Butler, M. O., Dhani, N. C., Lheureux, S., Wilson, M. K., Welch, S. A., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.12.002 · Cited by 46
Chen, W.-Y., Tsai, Y.-C., Siu, M. K., Yeh, H.-L., Chen, C.-L., Yin, J., Huang, J., & Liu, Y.-N. (2017) · Oncogene · doi:10.1038/onc.2017.226 · Cited by 46
Velasco, M. A. D., & Uemura, H. (2017) · Current Opinion in Urology · doi:10.1097/mou.0000000000000462 · Cited by 48
Analysis of cabazitaxel‐resistant mechanism in human castration‐resistant prostate cancer
Hongo, H., Kosaka, T., & Oya, M. (2018) · Cancer Science · doi:10.1111/cas.13729 · Cited by 46
PI3K pathway in prostate cancer: All resistant roads lead to PI3K
Park, S., Kim, Y. S., Kim, D. Y., So, I., & Jeon, J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.09.001 · Cited by 45
Li, Y., Liu, Y., Xu, H., Jiang, G., der Jeught, K. V., Fang, Y., Zhou, Z., Zhang, L., Frieden, M., Wang, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06811-z · Cited by 47
RetractedMicroRNA‐200a suppresses prostate cancer progression through BRD4/AR signaling pathway
Guan, H., You, Z., Wang, C., Fang, F., Peng, R., Mao, L., Xu, B., & Chen, M. (2019) · Cancer Medicine · doi:10.1002/cam4.2029 · Cited by 46
Patel, R., Brzezińska, E. A., Repiščák, P., Ahmad, I., Mui, E. J., Gao, M., Blomme, A., Harle, V. J., Tan, E. H., Malviya, G., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1684 · Cited by 49
CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer
Lei, H., Wang, Z., Jiang, D., Liu, F., Liu, M., Lei, X., Yang, Y., He, B., Yan, M., Huang, H. W., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04027-6 · Cited by 47
Sena, L. A., Kumar, R., Sanin, D. E., Thompson, E. A., Rosen, D. M., Dalrymple, S. L., Antony, L., Yang, Y., Gomes‐Alexandre, C., Hicks, J. L., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162396 · Cited by 46
“This demonstrates that AR activity in advanced CRPC is controlled by factors beyond protein abundance, which likely includes activating or inactivating gene mutations in AR and activity and abundance of AR cofactors and regulators (27, 28).”
BackgroundResultWNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth
Wang, K., Ma, F., Arai, S., Wang, Y., Varkaris, A. S., Poluben, L., Voznesensky, O. S., Xie, F., Zhang, X., Yuan, X., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3003 · Cited by 45
Self-citationZhang, T., Zhao, F., Lin, Y., Liu, M., Zhou, H., Cui, F., Jin, Y., Chen, L., & Sheng, X. (2024) · Theranostics · doi:10.7150/thno.92336 · Cited by 46
“Recently, several large-scale comprehensive studies have greatly advanced our understanding of the molecular complexity of PCa microenvironment [4, 5, 9-12 , 15-20 15-20].”
BackgroundMethodInfluentialLi, H., Wang, Z., Tang, K., Zhou, H., Liu, H., Yan, L., Guan, W., Chen, K., Xu, H., & Ye, Z. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.01.004 · Cited by 46
AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination
Haffner, M. C., Esopi, D., Chaux, A., Gürel, M., Ghosh, S., Vaghasia, A. M., Tsai, H. K., Kim, K., Castagna, N., Lam, H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00084-8 · Cited by 44
Pan, H., Jansson, K. H., Beshiri, M. L., Yin, J., Fang, L., Agarwal, S., Nguyen, H. M., Corey, E., Zhang, Y., Liu, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20424 · Cited by 46
Egevad, L., Delahunt, B., Kristiansen, G., Samaratunga, H., & Varma, M. (2017) · Pathology · doi:10.1016/j.pathol.2017.09.008 · Cited by 45
Functional characterization of a novel somatic oncogenic mutation of PIK3CB
Whale, A. D., Colman, L., Lensun, L., Rogers, H. L., & Shuttleworth, S. J. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.63 · Cited by 45
MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer
Lin, H., Nikolić, I., Yang, J., Castillo, L. E., Deng, N., Chan, C., Yeung, N. K., Dodson, E., Elsworth, B., Spielman, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26050-y · Cited by 45
Panigrahi, P., Jere, A., & Anamika, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196588 · Cited by 45
BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK
Shafran, J. S., Andrieu, G. P., Győrffy, B., & Denis, G. V. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1279 · Cited by 47
Oncogenic ETS Factors in Prostate Cancer
Nicholas, T. R., Strittmatter, B. G., & Hollenhorst, P. C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_18 · Cited by 49
Direct interaction of β‐catenin with nuclear ESM1 supports stemness of metastatic prostate cancer
Pan, K., Lee, W.-J., Chou, C., Yang, Y., Chang, Y., Chien, M., Hsiao, M., & Hua, K. (2020) · The EMBO Journal · doi:10.15252/embj.2020105450 · Cited by 43
Takayama, K., Kosaka, T., Suzuki, T., Hongo, H., Oya, M., Fujimura, T., Suzuki, Y., & Inoue, S. (2021) · Nature Communications · doi:10.1038/s41467-021-23974-4 · Cited by 45
Yan, Y., Zhou, B. O., Chen, Q., Vasquez, A., Kamra, M., Chatterjee, A., Lee, Y., Yuan, X., Ellis, L., Vizio, D. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28340-6 · Cited by 46
RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer
Miao, C., Tsujino, T., Takai, T., Gui, F., Tsutsumi, T., Sztupinszki, Z. M., Wang, Z., Azuma, H., Szállási, Z., Mouw, K. W., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl9794 · Cited by 46
Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities
Kumari, S., Sharma, V., Tiwari, R., Maurya, J. P., Subudhi, B. B., & Senapati, D. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174807 · Cited by 47
MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation
Ma, J., Li, L., Ma, B., Liu, T., Wang, Z., Ye, Q., Peng, Y., Wang, B., Chen, Y., Xu, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45796-w · Cited by 48
Self-citationZhao, S. G., Bootsma, M., Zhou, S., Shrestha, R., Moreno-Rodriguez, T., Lundberg, A., Pan, C., Arlidge, C., Hawley, J. R., Foye, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01826-3 · Cited by 42
“A plateau of amplification and 5hmC/hypomethylation of both the AR gene itself and its regulatory plexus of coampli-fied enhancers, is thought to be a critical driver of overexpression and resistance to therapies targeting AR 4,5,7,11,12 .”
Self-citation
Metadata
- Authors
- Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., Beltran, H., Abida, W., Bradley, R. K., Vinson, J., Cao, X., Vats, P., Kunju, L. P., Hussain, M., Feng, F. Y., Tomlins, S. A., Cooney, K. A., Smith, D. C., Brennan, C., Siddiqui, J., Mehra, R., Chen, Y., Rathkopf, D. E., Morris, M. J., Solomon, S. B., Durack, J. C., Reuter, V. E., Gopalan, A., Gao, J., Loda, M., Lis, R. T., Bowden, M., Balk, S. P., Gaviola, G., Sougnez, C., Gupta, M., Yu, E. Y., Mostaghel, E. A., Cheng, H. H., Mulcahy, H., True, L. D., Plymate, S. R., Dvinge, H., Ferraldeschi, R., Flohr, P., Miranda, S., Zafeiriou, Z., Tunariu, N., Mateo, J., Perez-Lopez, R., Demichelis, F., Robinson, B. D., Schiffman, M., Nanus, D. M., Tagawa, S. T., Sigaras, A., Eng, K. W., Elemento, O., Sboner, A., Heath, E. I., Scher, H. I., Pienta, K. J., Kantoff, P., de Bono, J. S., Rubin, M. A., Nelson, P. S., Garraway, L. A., Sawyers, C. L., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Memorial Sloan Kettering Cancer Center (US)
- NewYork–Presbyterian Hospital (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- Royal Marsden NHS Foundation Trust (GB)
- Howard Hughes Medical Institute (US)
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- University of Washington Medical Center (US)
- University of Trento (IT)
- Cornell University (US)
- Wayne State University (US)
- Johns Hopkins University (US)
- Corresponding author
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- ORCID
- Robinson, Dan
- Schultz, Nikolaus
- Mosquera, Juan-Miguel
- Montgomery, Bruce
- Taplin, Mary-Ellen
- Pritchard, Colin C.
- Attard, Gerhardt
- Beltran, Himisha
- Abida, Wassim
- Bradley, Robert K.
- Vinson, Jake
- Cao, Xuhong
- Vats, Pankaj
- Kunju, Lakshmi P.
- Hussain, Maha
- Feng, Felix Y.
- Tomlins, Scott A.
- Cooney, Kathleen A.
- Smith, David C.
- Brennan, Christine
- Siddiqui, Javed
- Mehra, Rohit
- Chen, Yu
- Rathkopf, Dana E.
- Morris, Michael J.
- Solomon, Stephen B.
- Durack, Jeremy C.
- Gopalan, Anuradha
- Gao, Jianjiong
- Loda, Massimo
- Lis, Rosina T.
- Bowden, Michaela
- Gupta, Manaswi
- Yu, Evan Y.
- Mostaghel, Elahe A.
- Cheng, Heather H.
- Mulcahy, Hyojeong
- True, Lawrence D.
- Plymate, Stephen R.
- Dvinge, Heidi
- Flohr, Penny
- Miranda, Susana
- Zafeiriou, Zafeiris
- Tunariu, Nina
- Demichelis, Francesca
- Robinson, Brian D.
- Schiffman, Marc
- Nanus, David M.
- Tagawa, Scott T.
- Sigaras, Alexandros
- Eng, Kenneth W.
- Elemento, Olivier
- Sboner, Andrea
- Heath, Elisabeth I.
- Scher, Howard I.
- Pienta, Kenneth J.
- Kantoff, Philip
- Rubin, Mark A.
- Nelson, Peter S.
- Garraway, Levi A.
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 161
- Issue
- 5
- Pages
- 1215-1228
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4484602
- OpenAlex
- W1578291413
- Cited by
- 3,645
- References
- 64
- Citations by year
- 2026: 178 · 2025: 258 · 2024: 320 · 2023: 363 · 2022: 360 · 2021: 392 · 2020: 378 · 2019: 346 · 2018: 358 · 2017: 355 · 2016: 263 · 2015: 63
- FWCI
- 273.95
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-07-16)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Iris (University of Trento) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Cancer Research UK (13239)
- National Institute for Health and Care Research (CL-2008-22-001)
- Prostate Cancer UK (CEO13_2-002, PG12-49)
- National Institutes of Health (DP2OD002750)
- Medical Research Council (MR/M003272/1)
- National Human Genome Research Institute (UM1HG006508)
- National Cancer Institute (P50 CA 90381, R01CA136578, L30 CA111031, K08CA188615, R21CA128352, U01CA111275, P50CA090381, R01CA131945, UO1CA111275, L30 CA103810, R01CA116337, R01CA129435, P50CA069568, K08CA115927, R01CA092629, R01CA155169, R01CA193910, R01CA085912, P30CA008748, P01CA163227, P50CA097186, P50CA186786, P50CA092629, P30CA006516, R01CA193837)
- National Institute of General Medical Sciences (T32GM007266, R01GM107427)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- metastatic castration-resistant prostate cancer, exome sequencing, transcriptome sequencing, actionable genomic alterations, androgen receptor alterations, ETS gene fusions, TP53, PTEN, R-spondin, APC, β-catenin, BRCA2, BRCA1, ATM, germline pathogenic variants, precision medicine
- MeSH terms
- Humans, Male, Mutation, Neoplasm Metastasis, Cohort Studies, Gene Expression Profiling, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
